In conclusion, the identification of STK25 as a positive regulator of IRF5 in SLE could lead to the development of targeted therapeutic agents that could selectively inhibit IRF5 hyperactivation to reduce inflammation and disease burden. This evidence concerns the gene IRF5 and systemic lupus erythematosus.